Cargando…
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells
Tamoxifen is the standard first-line endocrine therapy for breast cancer, but recent data indicate that it is likely to be replaced by the effective aromatase inhibitors (AIs), in both the metastatic and adjuvant settings. Aromatase inhibitors induce complete oestrogen deprivation that leads to clin...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409948/ https://www.ncbi.nlm.nih.gov/pubmed/15477866 http://dx.doi.org/10.1038/sj.bjc.6602181 |